News/ News/ R&D Switch data back Chiesi/Protalix long-acting Fabry drug Phil Taylor Chiesi, Fabrazyme, Fabry disease, Protalix, rare disease, Replagal, Sanofi Genzyme, Takeda 0 Comment Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, Share X Switch data back Chiesi/Protalix long-acting Fabry drug https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/